Back to mobile site

More on KYMR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-33.0% Growth)
- Ratings (8.7 Score)
- Holders

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kymera Therapeutics (NQ:KYMR)
Delayed: 108.42 +2.44 (2.30%)
Prev. Close $105.98  
Open$104.58 
52 Wk High$ 
52 Wk Low$ 
Day High$108.65 
Day Low$103.45 
P/E N/A  
EPS$ 
Volume639,562 

Friends, Peers and Foes (?): BIIB, DYN, GILD, XENE, ACAD (more...)

Oct 5, 2026 06:57 AM Citi reiterates buy rating on Nektar Therapeutics with $151 target
Oct 5, 2026 05:24 AM Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
Oct 5, 2026 05:03 AM Kymera Therapeutics (KYMR) PT Raised to $150 at Citi
Oct 1, 2026 05:20 PM Form 4 Kymera Therapeutics, For: Oct 01 Filed by: Mainolfi Nello
Oct 1, 2026 04:10 PM Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello
Oct 1, 2026 06:30 AM Wells Fargo names 13 stocks as overweight tactical ideas
Oct 1, 2026 05:06 AM B.Riley Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Sep 24, 2026 05:36 AM Goldman Sachs Resumes Kymera Therapeutics (KYMR) at Early-Stage Biotech
Sep 23, 2026 08:41 AM Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'
Sep 21, 2026 04:34 PM Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel on Ph2b BROADEN2 Data
View All Articles

Entities mentioned with kymr

View All Entities